14.21
-4.74 (-25.01%)
| Penutupan Terdahulu | 18.95 |
| Buka | 18.81 |
| Jumlah Dagangan | 141,553 |
| Purata Dagangan (3B) | 10,427 |
| Modal Pasaran | 31,205,900 |
| Harga / Jualan (P/S) | 3.22 |
| Harga / Buku (P/B) | 8.12 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | 1,007.39% |
| EPS Cair (TTM) | -52.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 262.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.86% |
| Nisbah Semasa (MRQ) | 1.39 |
| Aliran Tunai Operasi (OCF TTM) | -28.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -14.94 M |
| Pulangan Atas Aset (ROA TTM) | -75.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -233.67% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Apollomics Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 36.50% |
| % Dimiliki oleh Institusi | 0.22% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |